Applied Genetic Technologies logo

AGTC - Applied Genetic Technologies Share Price

$4.04 -0.0  -0.2%

Last Trade - 15/04/21

Small Cap
Market Cap ÂŁ125.4m
Enterprise Value ÂŁ94.0m
Revenue ÂŁn/a
Position in Universe 4672nd / 6854
Unlock AGTC Revenue
Relative Strength (%)
1m -34.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -58.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.35 47.4 39.5 24.2 41.7 2.45 0.25 +0.8%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, AppliedGenetic Technologies Corp revenues decreased from $2.5M to$0K. Net loss increased 53% to $30.8M. Revenues reflectCollaboration and milestone revenue decrease from $2.3M to$0K, Grant revenue decrease from $156K to $0K. Higher netloss reflects Research and development - Balancing vaincrease of 64% to $16.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for AGTC
Graphical History


AGTC Revenue Unlock AGTC Revenue

Net Income

AGTC Net Income Unlock AGTC Revenue

Normalised EPS

AGTC Normalised EPS Unlock AGTC Revenue

PE Ratio Range

AGTC PE Ratio Range Unlock AGTC Revenue

Dividend Yield Range

AGTC Dividend Yield Range Unlock AGTC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AGTC EPS Forecasts Unlock AGTC Revenue
Profile Summary

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is in the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM), and optogenetics. The Company has approximately one preclinical program in otology and three preclinical programs targeting central nervous system disorders (CN), including adrenoleukodystrophy (ALD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company's optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated October 24, 2003
Public Since March 27, 2014
No. of Shareholders: 30
No. of Employees: 83
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 42,657,878
Free Float (0.0%)
Eligible for
AGTC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AGTC
Upcoming Events for AGTC
Frequently Asked Questions for Applied Genetic Technologies
What is the Applied Genetic Technologies share price?

As of 15/04/21, shares in Applied Genetic Technologies are trading at $4.04, giving the company a market capitalisation of ÂŁ125.4m. This share price information is delayed by 15 minutes.

How has the Applied Genetic Technologies share price performed this year?

Shares in Applied Genetic Technologies are currently trading at $4.04 and the price has moved by 5.19% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Applied Genetic Technologies price has moved by -29.3% over the past year.

What are the analyst and broker recommendations for Applied Genetic Technologies?

Of the analysts with advisory recommendations for Applied Genetic Technologies, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Applied Genetic Technologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Applied Genetic Technologies next release its financial results?

Applied Genetic Technologies is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Applied Genetic Technologies dividend yield?

Applied Genetic Technologies does not currently pay a dividend.

Does Applied Genetic Technologies pay a dividend?

Applied Genetic Technologies does not currently pay a dividend.

When does Applied Genetic Technologies next pay dividends?

Applied Genetic Technologies does not currently pay a dividend.

How do I buy Applied Genetic Technologies shares?

To buy shares in Applied Genetic Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Applied Genetic Technologies?

Shares in Applied Genetic Technologies are currently trading at $4.04, giving the company a market capitalisation of ÂŁ125.4m.

Where are Applied Genetic Technologies shares listed? Where are Applied Genetic Technologies shares listed?

Here are the trading details for Applied Genetic Technologies:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: AGTC
What kind of share is Applied Genetic Technologies?

Based on an overall assessment of its quality, value and momentum, Applied Genetic Technologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Applied Genetic Technologies share price forecast 2021?

Shares in Applied Genetic Technologies are currently priced at $4.04. At that level they are trading at 0.295% discount to the analyst consensus target price of 0.00.

Analysts covering Applied Genetic Technologies currently have a consensus Earnings Per Share (EPS) forecast of -1.964 for the next financial year.

How can I tell whether the Applied Genetic Technologies share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Applied Genetic Technologies. Over the past six months, the relative strength of its shares against the market has been -38.4%. At the current price of $4.04, shares in Applied Genetic Technologies are trading at -21.54% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Applied Genetic Technologies PE Ratio?

We were not able to find PE ratio data for Applied Genetic Technologies.

Who are the key directors of Applied Genetic Technologies?

Applied Genetic Technologies's management team is headed by:

Scott Koenig - CHM
Susan Washer - PRE
James Rosen - IND
Edward Hurwitz - IND
Ivana Magovcevic-Liebisch - IND
Stephen Potter - VPR
Mark Shearman - CSO
Anne VanLent - IND
William Sullivan - CFO
William Aliski - IND
Matthew Feinsod - EVP
Who are the major shareholders of Applied Genetic Technologies?

Here are the top five shareholders of Applied Genetic Technologies based on the size of their shareholding:

Empery Asset Management, L.P. Investment Advisor/Hedge Fund
Percentage owned: 9.22% (3.93m shares)
Stonepine Capital Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 5.33% (2.27m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 3.68% (1.57m shares)
InterWest Partners Venture Capital
Percentage owned: 3.29% (1.40m shares)
Portolan Capital Management, L.L.C. Investment Advisor/Hedge Fund
Percentage owned: 3.07% (1.31m shares)
Similar to AGTC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.